Botulinum toxin A(Medytox)

Total sales growth of 22.6% at CER 1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline ® , growing by 27.5% at CER Strong pipeline momentum with three Phase III readouts expected in H2 2026 Confirmation of full-year 2026 guidance 2 PARIS, FRANCE, 23 April 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026. Q1 2026 % change €m Actual CER Oncology 707.5 8.0 % 13.0 % Rare Disease 147.1 109.1 % 125.4 % Neuroscience 220.3 13.8 % 18.5 % Total Sales 1,074.9 17.0% 22.6% “Ipsen has delivered a strong start to 2026,” said David Loew, Chief Executive Officer, Ipsen. “We advanced our strategic priorities across the business, combining strong top‑line performance with continued pipeline progress. I am very pleased with the growth of our rare liver disease franchise with the performance of Iqirvo and Bylvay. Additionally, with three Phase III readouts expected this year and three new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth and deliver meaningful value for patients.” Full-year guidance 2026 Ipsen is confirming its financial guidance 3 for full-year 2026: Total sales growth greater than 13.0%, at constant currency, assuming accelerated sales growth of the portfolio excluding Somatuline and the growth of Somatuline sales due to generic lanreotide challenges. Based on the average level of exchange rates in March 2026, an adverse effect on total sales of around 1% of currencies is expected Core operating margin greater than 35.0% of total sales Upcoming 2026 milestones Ipsen anticipates several key milestones across its portfolio in 2026, including: Iqirvo ® (ELSPIRE trial) – Readout of pivotal Phase III in primary biliary cholangitis Bylvay ® (BOLD trial) – Readout of pivotal Phase III in biliary atresia Dysport ® (BEOND trials) – Readout of pivotal Phase III trials in chronic and episodic migraine Corabotase (IPN10200, LANTIC trial) – Readout of Phase II in lateral canthal lines and forehead lines Data from stage 1 of the Phase II LANTIC trial of corabotase (IPN10200) will be presented at the Music City SCALE (Symposium for Cosmetic Advances and Laser Education) 2026 symposium in May. Pipeline update On 30 January 2026, Ipsen expanded its pre‑clinical pipeline in rare neurodegenerative diseases through a global collaboration and exclusive option agreement with Origami Therapeutics. The partnership focuses on a research‑stage protein‑degrader program targeting genetic neurodegenerative diseases. Should Ipsen exercise its option following successful drug‑candidate nomination, the Company would assume full responsibility for global development and commercialization, reinforcing its strategy in rare neuroscience and first‑in‑class innovation. On 9 March 2026, Ipsen announced the voluntary withdrawal of Tazverik ® (tazemetostat) from all indications and all Ipsen markets, effective immediately, following emerging safety data from the ongoing Phase Ib/III SYMPHONY‑1 trial in follicular lymphoma. On 22 April 2026, following the positive European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) opinion, Ipsen was granted conditional marketing authorization by the European Commission (EC) for Ojemda ® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies. Approval is based on the pivotal Phase II FIREFLY-1 data demonstrating meaningful and durable tumor responses. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here ; webcast details can be found here . Calendar Ipsen intends to publish its half-year results on 30 July 2026. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the three-month period to 31 March 2026 (Q1 2026, the quarter), compared to the three-month period to 31 March 2025 (Q1 2025) unless stated otherwise. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com . Ipsen Contacts Investors Henry Wheeler henry.wheeler@ipsen.com +33 7 66 47 11 49 Khalid Deojee khalid.deojee@ipsen.com +33 6 66 01 95 26 Media Sally Bain sally.bain@ipsen.com +1 857 320 0517 Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96 Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers . The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com . 1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 2 Total sales growth greater than 13.0%, at constant currency and core operating margin greater than 35.0% of total sales. 3 Excludes any impact from potential late-stage (Phase III clinical development or later) business development transactions. Attachment Ipsen PR_Q1 2026_23042026

一分钟新闻速览  ●创尔生物胶原蛋白斩获欧盟TSE CEP证书 ●新氧发布25年Q4及全年财报  ●上海家化发布2025年年报  ●爱美客米诺地尔产品目前销售计划正在制定中  ●远想生物与联合丽格达成战略合作  ●爱美客夯实现有产品矩阵，通过适应症拓展和渠道深化巩固市场地位  ●锦波生物北京科研基地奠基 打造全球首个FAST胶原蛋白数据库及应用研究平台  ●博瑞医药GLP-1/GIP减重药Ⅰ期数据公布  ●泰国医美巨头SCL集团成立中国事业部，携手华媒品牌服务中国客户  ●复锐医疗科技：2025年经调整纯利为3100万美元 同比增长7.9% ●科笛集团发布2025年业绩：核心新品商业化驱动强劲增长  ●韩国Medytox将正式推出基于胆酸的减脂注射剂Nuviju  ●德胜生物与韩国B&P达成合作  ●赛隽生物完成超亿元Pre-C轮融资  ●珀莱雅与上海市皮肤病医院共建“皮肤临床科创实验室”  ●普洛药业：公司计划通过三年到五年的努力，将医美化妆品原料业务规模做到10亿元  ●CAPA江苏国际交流中心落地泰州 最新获批受理 1.创尔生物胶原蛋白斩获欧盟TSE CEP证书 2026年3月25日，创尔生物发布消息，其胶原蛋白产品正式获得欧洲药品质量管理局（EDQM）颁发的TSECEP认证（证书编号：CEP2025-482-Rev00，有效期至2031年3月17日），这标志着创尔生物在动物源生物材料安全控制、质量体系建设等方面已达到欧盟EDQM认证标准，为其拓展国际市场筑牢合规根基，也成为国内胶原蛋白行业对接国际高标准的重要突破。 2.新氧发布25年Q4及全年财报：营收15.23亿元 3月25日，新氧发布2025年第四季度及全年财务业绩报告。2025年第四季度，公司实现总收入4.61亿元，同比增长25%，创下单季度收入历史新高。 其中，连锁业务收入同比增长205%，连续9个季度保持高速增长，占公司总收入比重首次突破50%，成为第一大收入来源。 2025年全年，公司总收入达15.23亿元。截至2025年末，新氧青春诊所门店数量增至49家，覆盖15座城市，成为中国规模最大的轻医美连锁机构，活跃用户超17万人。 3.上海家化发布2025年年报 2026年3月25日晚间，上海家化披露2025年年报。报告显示，公司全年实现营业收入63.2亿元，同比增长11.2%；归母净利润2.7亿元，实现扭亏为盈。 分业务看，美妆板块成为核心增长引擎，全渠道收入同比增长53.7%，其中线上渠道同比增长60.6%；国内线上业务收入同比增长36.9%，占国内主营业务收入比重提升至44.4%。整体来看，线上转型对业绩拉动明显。 4.爱美客米诺地尔产品目前销售计划正在制定中 爱美客在接受调研者提问时表示，公司米诺地尔产品目前销售计划正在制定中，该产品为非处方药药品，拥有2%和5%两个规格，用于治疗男性型脱发和斑秃。 5.远想生物与联合丽格达成战略合作 2026年3月25日，远想生物与联合丽格集团在北京签署全面生态战略合作协议，双方将在抗衰老、问题肌肤治疗及AI数智化皮肤管理等领域展开深度合作。 根据合作内容，双方将围绕“医护一体”模式，打通院内治疗与居家护理场景，构建覆盖诊断、治疗及长期管理的全周期皮肤健康服务体系。同时，依托AI皮肤管理系统与再生医学产品，提升诊疗精准度与用户管理效率。 在资源协同方面，联合丽格将发挥其医生网络与机构布局优势，远想生物则提供再生医学产品及AI技术支持，双方还将推进新品开发、供应链协同、学术赋能及市场推广等多维合作。 6.爱美客夯实现有产品矩阵，通过适应症拓展和渠道深化巩固市场地位 爱美客在接受调研者提问时表示，公司夯实现有产品矩阵，通过适应症拓展和渠道深化巩固市场地位；此外，加速在研产品管线落地，注射用A型肉毒毒素已于2026年1月获批上市，司美格鲁肽注射液等产品临床试验稳步推进；同时，持续深化投资并购布局，积极拓展新的增长机会，为长远发展积蓄动能。 7.锦波生物北京科研基地奠基 打造全球首个FAST胶原蛋白数据库及应用研究平台 2026年3月25日，锦波医学人源化胶原蛋白FAST数据库与产品开发平台项目开工仪式在大兴生物医药产业基地隆重举行，全球首个以AI深度学习驱动的FAST胶原蛋白数据库及应用研究平台，正式进入实体化建设阶段。 该项目是锦波生物在胶原蛋白基础研究领域的关键布局，承载着公司迈向平台型生命材料企业升级的战略重任，旨在通过建立人工智能算力中心与高通量智能化实验平台，构建“干湿闭环”胶原蛋白创新研发体系，围绕人类健康、长寿与美丽，持续破解生命密码，提供全新的科学平台。 8.博瑞医药GLP-1/GIP减重药Ⅰ期数据公布 2026年3月24日，博瑞医药发布公告称，其自主研发的GLP-1/GIP双受体激动剂BGM0504片，在中美开展的Ⅰ期临床试验中取得积极结果，用于成人超重/肥胖治疗。 中国Ⅰ期研究显示，在10–80mg剂量范围内连续给药4周，整体安全性与耐受性良好，未出现严重不良事件；初步疗效方面，体重较基线下降约1.04%–5.56%。美国Ⅰ期研究同样未观察到严重不良事件，常见不良反应以轻中度胃肠道反应为主；5–8周治疗后，减重幅度约2.7%–8.2%，呈现一定剂量依赖趋势。 9.泰国医美巨头成立中国事业部，携手华媒品牌服务中国客户 泰国头条新闻社讯 2026年3月24日上午9时09分，泰国顶尖医美品牌SLC集团 (Aesthetic Answer Co., Ltd.) 与泰国亚洲大众集团（简称JRN）在曼谷隆重举行了战略合作签约仪式。此次签约标志着双方正式达成深度战略合作伙伴关系，全面开启泰国高端医美服务走向全球华人市场的新纪元。  10.复锐医疗科技：2025年经调整纯利为3100万美元 同比增长7.9% 3月23日晚间复锐医疗科技(01696.HK)发布公告，截至2025年12月31日止年度，实现收益3.65亿美元，同比增加5%；毛利为2.15亿美元，同比减少0.7%；母公司拥有人应占利润为1901.6万美元，同比减少24.3%；经调整纯利为3100万美元，同比增长7.9%；基本每股年内溢利4.06美仙，拟派末期股息每股0.095港元(含税)。 报告期内，集团的毛利同比减少0.7%至2.15亿美元。毛利率由2024年的62.1%减少至报告期内的58.9%。该减少主要是由于地域和产品组合转变以及新实施的进口关税。 11.科笛集团发布2025年业绩：核心新品商业化驱动强劲增长 2026年3月24日，科笛集团发布消息披露2025年经营业绩，公司全年收益约3.36亿元人民币，下半年收益约2.7亿元、环比增长约307%；销售及分销、研发及行政开支同比减少约1.09亿元，年内亏损同比减少约0.94亿元，截至2025年末现金及等价物等合计约7.88亿元，全年业绩迈向新高，实现经营提质增效的发展目标。 2025年科笛集团核心发展成果显著，两款全球首款重磅产品CU-40102（外用非那雄胺喷雾剂，商品名纷永维®）、CU-10201（外用4%米诺环素泡沫剂，商品名安佐清®）于2025年10月下旬在国内正式商业化销售，其中CU-40102还获香港卫生署上市批准，两款产品上市后快速拓展至数百家医院、药房、植发机构及主流电商平台，2025年内合计收入超1亿元，商业化势头良好。 12.韩国Medytox将正式推出基于胆酸的减脂注射剂Nuviju 近日，韩国Medytox宣布将于3月30日推出下颌减脂注射剂Nuviju，正式进军医美领域。该产品是韩国首款自研、以胆酸为核心成分的减脂注射剂，获韩国食药部认定为第40款国产新药，适用于改善中重度双下巴问题。 相较脱氧胆酸类产品，其配方适配人体生理酸碱度、无刺激辅料，能减轻肿胀、淤青等不良反应。24人参与的Ⅲ期临床显示，88.6%受试者改善等级至少一级，46.7%至少两级。 公司将依托合作医渠上市，与现有管线形成协同，后续重点提升品牌知名度、推动产品普及。 13.德胜生物与韩国B&P达成合作 2026年1月，德胜生物与韩国生物材料专业企业B&P Korea（代表理事：Bae Noh-eul）正式签署独家代理合同。根据协议，德胜生物将通过B&P Korea代理公司向韩国供应原料。 B&P Korea成立于2010年，在生物材料领域拥有深厚的市场积淀，客户网络覆盖韩国制药、生物、医疗及高端化妆品行业，优质客户资源百余家。在2014年至2025年期间，B&P Korea曾作为法国HTL公司在韩国市场的独家代理，率先将PDRN/PN作为进口原料引入韩国，在行业内起到了重要的引领与开拓作用。 14.赛隽生物完成超亿元Pre-C轮融资 近日，国际先进的干细胞创新药研发与生产企业——广州赛隽生物科技有限公司（以下简称“赛隽生物”）正式宣布完成超亿元人民币Pre-C轮融资。本轮融资由太平医疗健康基金深圳河套医疗子基金与粤财中垠基金联合领投，并由老股东松禾资本追加投资。所融资金将主要用于核心管线临床推进、商业化团队搭建、市场开拓及创新管线的临床前研发，为赛隽生物在干细胞创新药领域的临床开发及商业化落地提供坚实保障。 干细胞治疗作为细胞与基因治疗产业的核心代表，正迎来政策黄金期。2025年9月国务院审议通过的《生物医学新技术临床研究和临床转化应用管理条例》（“818新政”） 即将于今年5月实施，“临床研究备案 + 转化应用审批” 双轨模式落地，叠加国家药监局对细胞与基因治疗药品审评审批的持续优化，中国细胞疗法正从政策护航与技术突破的双重驱动中，迎来产业化的关键爆发期。 15.珀莱雅与上海市皮肤病医院共建“皮肤临床科创实验室” 3月18日，珀莱雅股份与上海市皮肤病医院合作共建“皮肤临床科创实验室”，并在上海完成揭牌。 根据合作内容，双方将围绕功效性护肤品研发、皮肤基础研究、临床验证及成果转化等方向开展协同，重点探索“产学研医”一体化的创新模式。实验室未来将聚焦皮肤机理研究、临床转化及功效评价体系建设，推动从科研到产品的证据闭环。 16.普洛药业：公司计划通过三年到五年的努力，将医美化妆品原料业务规模做到10亿元 3月20日，普洛药业在接受调研者提问时表示，公司计划通过三年到五年的努力，将医美化妆品原料业务规模做到10亿元。从现有客户订单和自有产品市场反馈来看，有信心实现这一目标。 17.CAPA江苏国际交流中心落地泰州 2026年3月22日，中国整形美容协会（CAPA）江苏省国际交流中心在泰州苏王医疗美容揭牌，标志着省级医美国际交流平台正式落地。该平台将引入国际专家、技术及产品资源，推动区域医美服务与学术交流规范化发展。 同期，苏王医美联合半岛、薇旖美、艾维岚等八家厂商组建“正品联盟”，并签署诚信承诺，涵盖正品溯源、“假一罚十”、厂商联保等内容，强化产品合规与质量保障。 此外，机构发布“苏式美学3.0”数字化审美体系，通过面部九大模块划分，实现个性化评估与整体设计，并同步推出相关白皮书。 「发现全球医美最前沿」